A scientific journey from discovery to validation of efficacy in cancer patients: HAMLET and alpha1-oleate

James C.S. Ho\textsuperscript{a,b}, Ines Ambite\textsuperscript{a}, K. H. Mok\textsuperscript{c}, Marek Babjuk\textsuperscript{d,e}, and Catharina Svanborg\textsuperscript{a}

\textsuperscript{a}Division of Microbiology, Immunology and Glycobiology, Department of Laboratory Medicine, Faculty of Medicine, Lund University, Lund, Sweden; \textsuperscript{b}Singapore Centre for Environmental Life Sciences Engineering (SCELSE), Nanyang Technological University, Singapore, Singapore; \textsuperscript{c}Trinity College Dublin, Trinity Biomedical Sciences Institute (TBSI), School of Biochemistry & Immunology, Dublin, Ireland; \textsuperscript{d}Department of Urology, Motol University Hospital, Prague, Czech Republic; \textsuperscript{e}2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic

\textbf{ABSTRACT}

The protein-lipid complex alpha1-oleate, derived from HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells), is identified as a molecular entity with significant therapeutic potential. Structural characterization of the complex and results of a successful placebo-controlled clinical trial are presented.

The N-terminal, 39-residue alpha-helical domain of alpha-lactalbumin forms a tumoricidal complex with oleic acid (alpha1-oleate), which is attractive to cancer cells, which internalize it, but end up being killed.\textsuperscript{1}

The complex reproduces the tumoricidal properties of HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells), first identified as the cause of unexpected tumor cell death.\textsuperscript{2,3} Lung carcinoma cells were killed by a fraction of human milk containing HAMLET and the effect was reproduced in a number of different carcinoma and lymphoma cell lines. The purified complex, formed by partially unfolded alpha-lactalbumin and oleic acid, triggered rapid tumor cell death by inserting itself into the plasma membrane, activating ion fluxes, perturbing Ras signaling and affecting membrane-enclosed organelles, including cell nuclei.\textsuperscript{4,5} Extensive data in tumor models and clinical studies later confirmed that protein-lipid complexes such as HAMLET have a significant therapeutic potential and low toxicity.\textsuperscript{6,7}

Characterization and large-scale production of a synthetic, peptide-based alpha1-oleate complex has allowed for full translation into the clinic. Potent effects of the alpha1-oleate complex were demonstrated in a single center, placebo controlled, double blinded Phase I/II interventional clinical trial of non-muscle invasive bladder cancer (NMIBC).\textsuperscript{1} Patients with suspected NMIBC were randomized 1:1 to receive alpha1-oleate or placebo during a period of 22 days, prior to endoscopic removal of the tumor by transurethral resection. Alpha1-oleate (1.7 mM) or placebo (phosphate-buffered saline) was administered intra-vesically on six occasions (30 ml, days 1, 3, 5, 8, 15 and 22). Demographic data, medical history and vital signs did not differ between the treatment and placebo groups.

We recorded highly significant differences between the alpha1-oleate-treated patients and the placebo group for several crucial efficacy variables. All primary end points of safety and efficacy of alpha1-oleate treatment were reached, as evaluated in an interim analysis.\textsuperscript{1} Intra-vesical instillations of alpha1-oleate triggered massive shedding of tumor cells and shed cells contained alpha1-oleate, confirming uptake by tumor tissue. The tumor size was reduced and treated tumors showed evidence of apoptosis, with a gradient from the lumen toward the interior of the tumor. By gene expression analysis of tumor tissue, massive inhibition of multiple cancer biofunctions was observed in the treatment group (Figure 1).

Native protein structure is often regarded as a prerequisite for biological function, through epitope-specific interactions and molecular fitness for specific cellular targets. Yet, this study suggests that a lack of structural definition may result in a gain of function.\textsuperscript{1} Native alpha-lactalbumin serves as a substrate specifier in the lactose-synthase complex but when partially unfolded, the protein forms oleic acid complexes with potent tumoricidal activity as first observed for the HAMLET complex.\textsuperscript{2,3,8}

Now the atomic-level structural basis for this gain-of-function was defined for the alpha1 peptide, by complementary nuclear magnetic resonance (NMR) analysis. Accompanying all-atom computational simulations were able to provide corroborating shallow free-energy landscapes and three-dimensional structural motifs that influenced fatty acid binding efficiency and tumoricidal activity. It was also shown that the apparently unrelated sarl alpha peptide can form oleic acid complexes with shared structural characteristics, involving a flexible peptide moiety and a fatty acid cluster.
The results suggest that a lack of structural definition may be key to the biological activity of the complex, in part by uncovering different conformations and exposing peptide motifs that are unavailable in the native state.

It may be speculated that a loss of tertiary structural definition may enable a number of proteins to gain essential functions in different tissue environments, where fatty acid cofactors are present.\(^1\)\(^{-3}\) A plausible scenario is that gain-of-function may allow protein-lipid complexes to target aberrant cells, in a process similar to tumor immune surveillance.

NMIBC has been declared a great, unmet medical need, due to high recurrence rates, a lack of new effective treatments and limited supply of recommended Bacillus Calmette–Guérin (BCG) immunotherapy or chemotherapy (Mitomycin) for intravesical use.\(^9\),\(^10\) In view of the low toxicity of alpha1-oleate observed so far, liberal intravesical administration in early stage NMIBC might be an interesting approach to postponing the introduction of more toxic and invasive therapeutic options. The long-term goal is to attack tumors with better precision, thus avoiding some of the toxicity that accompanies treatments currently used for bladder cancer.

**Disclosure statement**

C.S. holds shares in HAMLET Pharma, as a representative of scientists in the HAMLET group. Patents protecting the use of the alpha1-oleate complex have been granted. Other authors declare no conflict of interest.

**Funding**

This work was supported by the Swedish Research Council (Vetenskapsrådet), the Swedish Cancer Society (Cancerfonden) and HAMLET Pharma. Support to the Svanborg group was further provided from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 954360.

**References**

1. Brisuda A, Ho JCS, Kandiylal PS, Ng JTY, Ambite I, Butler DSC, Háček J, Wan MLY, Tran TH, Nadeem A, et al. Bladder cancer therapy using a conformationally fluid tumoricidal peptide complex. Nat Commun. 2021;12(1):3427. doi:10.1038/s41467-021-23748-y.

2. Hakansson A, Zhivotovsky B, Orrenius S, Sabharwal H, Svanborg C. Apoptosis induced by a human milk protein. Proc Natl Acad Sci U S A. 1995;92:8064–8068. doi:10.1073/pnas.92.17.8064.
3. Svensson M, Hakansson A, Mossberg AK, Linse S, Svanborg C. Conversion of alpha-lactalbumin to a protein inducing apoptosis. Proc Natl Acad Sci U S A. 2000;97:4221–4226. doi:10.1073/pnas.97.8.4221.

4. Ho JC, Nadeem A, Rydstrom A, Puthia M, Svanborg C. Targeting of nucleotide-binding proteins by HAMLET—a conserved tumor cell death mechanism. Oncogene. 2016;35:897–907. doi:10.1038/onc.2015.144.

5. Nadeem A, Sanborn J, Gettel DL, James HCS, Rydström A, Ngassam VN, Klausen TK, Pedersen SF, Lam M, Parikh AN, et al. Protein receptor-independent plasma membrane remodeling by HAMLET: a tumoricidal protein-lipid complex. Sci Rep. 2015;5:16432. doi:10.1038/srep16432.

6. Gustafsson L, Leijonhufvud I, Aronsson A, Mossberg AK, Svanborg C. Treatment of skin papillomas with topical alpha-lactalbumin-oleic acid. N Engl J Med. 2004;350:2663–2672. doi:10.1056/NEJMoA032454.

7. Tran TH, Ambite I, Butler D, Wan MLY, Tran TH, Höglund U, Babjuk M, Svanborg C. Bladder cancer therapy without toxicity—a dose-escalation study of alpha1-oleate. Int J Cancer. 2020;147:2479–2492. doi:10.1002/ijc.33019.

8. Pettersson-Kastberg J, Mossberg A-K, Trulsson M, Yong YJ, Min S, Lim Y, O’Brien JE, Svanborg C, Mok KH. alpha-Lactalbumin, engineered to be nonnative and inactive, kills tumor cells when in complex with oleic acid: a new biological function resulting from partial unfolding. J Mol Biol. 2009;394:994–1010. doi:10.1016/j.jmb.2009.09.026.

9. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96–108. doi:10.1016/j.eururo.2016.06.010.

10. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M. EAU guidelines on non-muscle-invasive urothelial Carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–461. doi:10.1016/j.eururo.2016.05.041.